

# David Goldstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/546740/publications.pdf>

Version: 2024-02-01

280  
papers

17,544  
citations

28242

55  
h-index

15249

126  
g-index

285  
all docs

285  
docs citations

285  
times ranked

19943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. <i>New England Journal of Medicine</i> , 2013, 369, 1691-1703.	13.9	5,097
2	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1844.	3.8	801
3	Chemotherapy-induced peripheral neurotoxicity: A critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 419-437.	157.7	547
4	Desmoplastic Reaction in Pancreatic Cancer. <i>Pancreas</i> , 2004, 29, 179-187.	0.5	530
5	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju413-dju413.	3.0	487
6	Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells. <i>Cancer Research</i> , 2008, 68, 2085-2093.	0.4	417
7	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	0.8	351
8	Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis. <i>American Journal of Pathology</i> , 2010, 177, 2585-2596.	1.9	304
9	Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer/Italian Sarcoma Group/Australasian Gastrointestinal Trials Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5795-5804.	0.8	266
10	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
11	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt347.	3.0	231
12	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , 2009, 132, 2712-2723.	3.7	198
13	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , 2005, 32, 51-60.	1.0	194
14	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	2.1	189
15	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	0.8	183
16	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	1.1	182
17	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. <i>PLoS ONE</i> , 2017, 12, e0170814.	1.1	177
18	STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. <i>International Journal of Oncology</i> , 2012, 41, 1181-1191.	1.4	172

#	ARTICLE	IF	CITATIONS
19	Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. <i>Supportive Care in Cancer</i> , 2018, 26, 685-700.	1.0	172
20	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.	1.9	171
21	What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. <i>Clinical Chemistry</i> , 1998, 44, 1951-1958.	1.5	169
22	Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. <i>British Journal of Surgery</i> , 2015, 102, 1459-1472.	0.1	158
23	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.	0.8	153
24	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	0.8	148
25	Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 4089-4095.	0.8	142
26	Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. <i>Annals of Oncology</i> , 2019, 30, 1472-1478.	0.6	141
27	Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. <i>European Journal of Cancer</i> , 2017, 73, 22-29.	1.3	130
28	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 4000-4000.	0.8	125
29	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. <i>Oncologist</i> , 2015, 20, 143-150.	1.9	123
30	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. <i>Frontiers in Physiology</i> , 2014, 5, 141.	1.3	122
31	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. <i>Clinical Cancer Research</i> , 2012, 18, 3170-3179.	3.2	116
32	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1805-1812.	0.8	114
33	Key role of pancreatic stellate cells in pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 194-200.	3.2	103
34	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.	3.6	97
35	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	2.9	88
36	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016, 27, 134-140.	0.6	88

#	ARTICLE	IF	CITATIONS
37	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2016, 27, 654-660.	0.6	87
38	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 998-1004.	2.9	84
39	If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1333-1344.	1.9	84
40	Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. <i>Annals of Oncology</i> , 2014, 25, 1643-1649.	0.6	81
41	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 114, 269-280.	2.9	81
42	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	1.1	79
43	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 188-194.	2.9	76
44	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75
45	The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. <i>Carcinogenesis</i> , 2014, 35, 1891-1900.	1.3	72
46	Anxiety, depression and quality of life in people with pancreatic cancer and their carers. <i>Pancreatology</i> , 2017, 17, 321-327.	0.5	71
47	Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 76722-76739.	0.8	70
48	Pancreatic cancer: The microenvironment needs attention too!. <i>Pancreatology</i> , 2015, 15, S32-S38.	0.5	69
49	A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. <i>Biomacromolecules</i> , 2016, 17, 2337-2351.	2.6	68
50	Administration of Imiquimod, an Interferon Inducer, in Asymptomatic Human Immunodeficiency Virus-Infected Persons to Determine Safety and Biologic Response Modification. <i>Journal of Infectious Diseases</i> , 1998, 178, 858-861.	1.9	66
51	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. <i>Cancer Research</i> , 2021, 81, 3461-3479.	0.4	62
52	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , 2016, 115, 281-289.	2.9	61
53	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA4003-LBA4003.	0.8	61
54	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , 2017, 25, 3485-3493.	1.0	59

#	ARTICLE	IF	CITATIONS
55	Communicating in a multicultural society II: Greek community attitudes towards cancer in Australia. <i>Internal Medicine Journal</i> , 2002, 32, 289-296.	0.5	58
56	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. <i>Frontiers in Physiology</i> , 2014, 5, 2.	1.3	57
57	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA148-LBA148.	0.8	57
58	Î²III-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 2235-2249.	0.8	57
59	Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 3849-3857.	1.0	56
60	Fatigue and psychological distress â€œ exploring the relationship in women treated for breast cancer. <i>European Journal of Cancer</i> , 2004, 40, 1689-1695.	1.3	54
61	A Serious Complication of Selected Internal Radiation Therapy: Case Report and Literature Review. <i>Oncologist</i> , 2010, 15, 830-835.	1.9	54
62	A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. <i>Psycho-Oncology</i> , 2016, 25, 150-157.	1.0	53
63	Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 478-480.	13.9	52
64	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016, 16, 22.	1.1	52
65	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
66	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , 2017, 128, 1166-1175.	0.7	50
67	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , 2021, 4, e2036695.	2.8	49
68	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 469-478.	0.6	48
69	Migrant Health in Cancer: Outcome Disparities and the Determinant Role of Migrant-Specific Variables. <i>Oncologist</i> , 2015, 20, 523-531.	1.9	46
70	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. <i>Biomaterials</i> , 2020, 240, 119742.	5.7	46
71	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , 2016, 55, 15-26.	1.3	45
72	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 74-84.	0.6	45

#	ARTICLE	IF	CITATIONS
73	Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , 2020, 122, 1486-1495.	2.9	45
74	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	0.6	44
75	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. <i>International Journal of Cancer</i> , 2014, 135, 996-1001.	2.3	42
76	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	1.1	41
77	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring <em>EGFR</em> mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5461-5473.	1.0	41
78	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	1.1	41
79	Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients. <i>Health Expectations</i> , 2017, 20, 886-895.	1.1	40
80	Modern management of pancreatic carcinoma. <i>Internal Medicine Journal</i> , 2004, 34, 475-481.	0.5	38
81	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , 2019, 15, 1295-1302.	1.1	37
82	Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). <i>European Journal of Cancer</i> , 2016, 52, 85-91.	1.3	36
83	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , 2016, 27, 648-653.	0.6	36
84	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2007, 97, 464-471.	2.9	35
85	Targeting HGF/c-MET Axis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9170.	1.8	35
86	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSC), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)â. <i>Annals of Oncology</i> , 2021, 32, 533-541.	0.6	34
87	The Potential of panHER Inhibition in Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 2.	1.3	33
88	Information needs of the Chinese community affected by cancer: A systematic review. <i>Psycho-Oncology</i> , 2017, 26, 1433-1443.	1.0	33
89	Gastrointestinal Stromal Tumours: Correlation of <sup>18</sup>F-FDG Gamma Camera-Based Coincidence Positron Emission Tomography with CT for the Assessment of Treatment Response â An AGITG Study. <i>Oncology</i> , 2005, 69, 326-332.	0.9	31
90	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA4003-LBA4003.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Describing Patterns of Care in Pancreatic Cancer. <i>Pancreas</i> , 2015, 44, 1259-1265.	0.5	30
92	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018, 118, 947-954.	2.9	30
93	Chemotherapy-induced peripheral neuropathyâ€”patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.	1.0	30
94	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. <i>Clinical Colorectal Cancer</i> , 2006, 6, 297-304.	1.0	29
95	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	2.2	29
96	Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. <i>British Journal of Haematology</i> , 1997, 97, 38-45.	1.2	28
97	â€œI might not have cancer if you didnâ€™t mention itâ€”a qualitative study on information needed by culturally diverse cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 409-418.	1.0	27
98	Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals. <i>European Journal of Oncology Nursing</i> , 2017, 26, 83-90.	0.9	27
99	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , 2021, 11, 1944.	1.6	27
100	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 949-955.	2.3	27
101	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , 2017, 2, e000152.	2.0	26
102	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
103	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4001-4001.	0.8	25
104	Determinants of Outcomes Following Resection for Pancreatic Cancerâ€”a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1471-1481.	0.9	24
105	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine. <i>Pancreas</i> , 2017, 46, 203-208.	0.5	24
106	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 821-828.	2.3	24
107	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	1.3	23
108	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. <i>European Journal of Cancer</i> , 2016, 53, 96-104.	1.3	23

#	ARTICLE	IF	CITATIONS
109	Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. <i>Neuroscience Letters</i> , 2019, 694, 14-19.	1.0	23
110	Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. <i>Anticancer Research</i> , 2016, 36, 5765-5772.	0.5	23
111	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. <i>Frontiers in Nutrition</i> , 2015, 2, 10.	1.6	22
112	Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. <i>Supportive Care in Cancer</i> , 2016, 24, 3589-3599.	1.0	22
113	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. <i>Muscle and Nerve</i> , 2018, 57, 650-658.	1.0	22
114	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , 2020, 21, 44-58.	0.7	22
115	Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 832-837.	2.9	21
116	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1023-1032.	0.6	21
117	Patient perspectives on molecular tumor profiling: "Why wouldn't you?" <i>BMC Cancer</i> , 2019, 19, 753.	1.1	21
118	Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview. <i>Psychosomatic Medicine</i> , 2014, 76, 379-388.	1.3	20
119	Factors associated with quality of care for patients with pancreatic cancer in Australia. <i>Medical Journal of Australia</i> , 2016, 205, 459-465.	0.8	20
120	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , 2019, 21, 444-455.	0.1	20
121	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , 2023, 17, 222-236.	1.5	20
122	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <i>Oncotarget</i> , 2016, 7, 21496-21509.	0.8	20
123	Circulating pancreatic stellate (stromal) cells in pancreatic cancer—a fertile area for novel research. <i>Carcinogenesis</i> , 2017, 38, 588-591.	1.3	19
124	Phase II study of vinflunine in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 429-434.	1.2	18
125	Post-cancer fatigue is not associated with immune activation or altered cytokine production. <i>Annals of Oncology</i> , 2012, 23, 2890-2895.	0.6	18
126	Delineating the Role of $\beta$ -Tubulins in Pancreatic Cancer: $\beta$ -Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. <i>Neoplasia</i> , 2016, 18, 753-764.	2.3	18



#	ARTICLE	IF	CITATIONS
127	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2506-2515.	0.7	18
128	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4005-4005.	0.8	18
129	Oncology service initiatives and research in regional Australia. <i>Australian Journal of Rural Health</i> , 2015, 23, 40-48.	0.7	17
130	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 178-178.	0.8	17
131	It's all good on the surface: care coordination experiences of migrant cancer patients in Australia. <i>Supportive Care in Cancer</i> , 2016, 24, 2403-2410.	1.0	16
132	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
133	Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. <i>Palliative and Supportive Care</i> , 2018, 16, 534-543.	0.6	16
134	TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 361-367.	1.1	15
135	Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1-7.	1.1	15
136	Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1159.	1.8	15
137	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 326-336.	0.7	15
138	Impact of STAT3 inhibition on survival of osteosarcoma cell lines. <i>Anticancer Research</i> , 2014, 34, 6537-45.	0.5	15
139	The GOFURTO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> , 2012, 106, 61-69.	2.9	14
140	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> , 2016, 204, 419-422.	0.8	14
141	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. <i>Pancreatology</i> , 2016, 16, 873-881.	0.5	14
142	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. <i>BMC Cancer</i> , 2018, 18, 454.	1.1	14
143	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , 2019, 13, 495-502.	1.5	14
144	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. <i>Journal of Surgical Oncology</i> , 2019, 119, 489-496.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> , 2016, 16, 1106-1112.	0.5	13
146	The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , 2020, 18, 403-417.	2.2	13
147	ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA4505-LBA4505.	0.8	13
148	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. <i>Oncotarget</i> , 2017, 8, 9216-9229.	0.8	13
149	ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA4505-LBA4505.	0.8	13
150	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 993-1004.	1.1	12
151	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. <i>Oncologist</i> , 2016, 21, 618-625.	1.9	12
152	Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds. <i>Supportive Care in Cancer</i> , 2019, 27, 1951-1960.	1.0	12
153	Oxaliplatin-induced haematological toxicity and splenomegaly in mice. <i>PLoS ONE</i> , 2020, 15, e0238164.	1.1	12
154	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. <i>BMC Cancer</i> , 2021, 21, 936.	1.1	12
155	EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1118-1123.	0.6	11
156	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172307.	1.1	11
157	Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 383-397.	0.6	11
158	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. <i>Patient Education and Counseling</i> , 2021, 104, 944-952.	1.0	11
159	Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. <i>Pancreatology</i> , 2021, 21, 103-114.	0.5	11
160	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€™Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	0.8	11
161	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521.	0.8	11
162	Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4515-4515.	0.8	11

#	ARTICLE	IF	CITATIONS
163	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.	1.6	11
164	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> , 2022, 31, 3091-3107.	1.5	11
165	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. <i>BMC Cancer</i> , 2018, 18, 389.	1.1	10
166	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 519-525.	1.1	9
167	Using a Delphi process to determine optimal care for patients with pancreatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 105-114.	0.7	9
168	A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. <i>Contemporary Clinical Trials</i> , 2018, 70, 135-138.	0.8	9
169	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018, 118, 1084-1088.	2.9	9
170	Accuracy and Prognostic Significance of Oncologists'™ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1102-e1107.	1.9	9
171	Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , 2020, 124, 232-244.	0.9	9
172	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2021, 10, 100189.	1.3	9
173	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4101-4101.	0.8	9
174	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)â€”An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4136-TPS4136.	0.8	9
175	APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS473-TPS473.	0.8	8
176	Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis. <i>Quality of Life Research</i> , 2014, 23, 2819-2830.	1.5	7
177	Biliary Stenting in Patients With Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 80-86.	0.5	7
178	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e204721.	2.8	7
179	HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 2763.	1.7	7
180	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , 2021, 21, 221-237.	2.2	7

#	ARTICLE	IF	CITATIONS
181	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. Journal of Clinical Oncology, 2015, 33, 9-9.	0.8	7
182	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. European Urology Focus, 2016, 2, 341-342.	1.6	6
183	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. International Journal of Oncology, 2018, 52, 2143-2154.	1.4	6
184	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. Cancers, 2021, 13, 2427.	1.7	6
185	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 993-1002.	0.4	6
186	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2013, 31, 4059-4059.	0.8	6
187	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. ANZ Journal of Surgery, 2018, 88, 870-875.	0.3	5
188	Advanced cancer patient preferences for receiving molecular profiling results. Psycho-Oncology, 2020, 29, 1533-1539.	1.0	5
189	Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. Pancreatology, 2020, 20, 1458-1464.	0.5	5
190	Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. Public Health Research and Practice, 2021, 31, .	0.7	5
191	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. Patient Education and Counseling, 2022, 105, 452-459.	1.0	5
192	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2013, 31, 4058-4058.	0.8	5
193	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).. Journal of Clinical Oncology, 2014, 32, TPS4162-TPS4162.	0.8	5
194	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. Journal of Clinical Oncology, 2015, 33, 4115-4115.	0.8	5
195	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	1.7	5
196	Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Management and Research, 2018, Volume 10, 1389-1396.	0.9	4
197	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Supportive Care in Cancer, 2021, 29, 6379-6387.	1.0	4
198	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology, 2014, 32, 254-254.	0.8	4

#	ARTICLE	IF	CITATIONS
199	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. Journal of Clinical Oncology, 2015, 33, 9571-9571.	0.8	4
200	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. Journal of Clinical Oncology, 2015, 33, 387-387.	0.8	4
201	Initial survival outcomes for the AGITG GAP study â€” a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2016, 34, 4105-4105.	0.8	4
202	Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2017, 35, 4109-4109.	0.8	4
203	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	0.8	4
204	Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. Patient Education and Counseling, 2022, 105, 2206-2216.	1.0	4
205	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 2007, 6, 578-582.	1.0	3
206	Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e291-e297.	0.7	3
207	The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. Journal of Gastrointestinal Oncology, 2017, 8, E10-E15.	0.6	3
208	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. Acta Oncologica, 2020, 59, 20-27.	0.8	3
209	Cancer survivorship outcomes in immigrants.. Journal of Clinical Oncology, 2012, 30, 6111-6111.	0.8	3
210	Predictors of resilience in women treated for breast cancer: A prospective study.. Journal of Clinical Oncology, 2012, 30, 9044-9044.	0.8	3
211	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157.	0.8	3
212	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2016, 34, 64-64.	0.8	3
213	Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.. Journal of Clinical Oncology, 2017, 35, 4120-4120.	0.8	3
214	Patientsâ€™ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. Journal of Clinical Oncology, 2018, 36, 3602-3602.	0.8	3
215	NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. Journal of Clinical Oncology, 2019, 37, TPS4156-TPS4156.	0.8	3
216	An Orthotopic Resectional Mouse Model of Pancreatic Cancer. Journal of Visualized Experiments, 2020, , .	0.2	3

#	ARTICLE	IF	CITATIONS
217	Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 175-179.	0.7	2
218	Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 170-174.	0.7	2
219	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 951-964.	1.1	2
220	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , 2018, 57, 615-621.	1.0	2
221	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 1274-1284.	0.5	2
222	Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 115-122.	0.7	2
223	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. <i>Cancer Epidemiology</i> , 2020, 67, 101773.	0.8	2
224	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. <i>Journal of Genetic Counseling</i> , 2022, 31, 96-108.	0.9	2
225	Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Gait and Posture</i> , 2021, 89, 178-185.	0.6	2
226	Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 phase II PAN1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 228-228.	0.8	2
227	Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 333-333.	0.8	2
228	The effect of exercise intensity on exercise-induced hypoalgesia in cancer survivors: A randomized crossover trial. <i>Physiological Reports</i> , 2021, 9, e15047.	0.7	2
229	GOFURTO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). <i>Journal of Clinical Oncology</i> , 2009, 27, 4616-4616.	0.8	2
230	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4027-4027.	0.8	2
231	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. <i>PLoS ONE</i> , 2020, 15, e0243312.	1.1	2
232	Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 725-734.	0.7	2
233	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366.	0.8	2
234	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. <i>Targeted Oncology</i> , 2022, 17, 95.	1.7	2

#	ARTICLE	IF	CITATIONS
235	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2022, 30, 5965-5974.	1.0	2
236	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. <i>Chinese Clinical Oncology</i> , 2013, 2, 22.	0.4	2
237	The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 187-192.	0.7	1
238	Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , 2020, 123, 1466-1466.	2.9	1
239	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4172-TPS4172.	0.8	1
240	Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 4100-4100.	0.8	1
241	Disparities in quality-of-life outcomes in immigrant cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16507-e16507.	0.8	1
242	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9602-9602.	0.8	1
243	Correlation of <i>KIT</i> and <i>PDGFRA</i> mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10549-10549.	0.8	1
244	Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9537-9537.	0.8	1
245	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. <i>Journal of Clinical Oncology</i> , 2014, 32, 428-428.	0.8	1
246	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15111-e15111.	0.8	1
247	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4140-TPS4140.	0.8	1
248	<i>nab</i> -paclitaxel ( <i>nab</i> -P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4153-TPS4153.	0.8	1
249	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 235-235.	0.8	1
250	Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel ( <i>nab</i> -P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , 2015, 33, 382-382.	0.8	1
251	Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 227-227.	0.8	1
252	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4618-4618.	0.8	1

#	ARTICLE	IF	CITATIONS
253	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. <i>Oncotarget</i> , 2020, 11, 46-61.	0.8	1
254	Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4067-4067.	0.8	1
255	Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4053-4053.	0.8	1
256	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4024-4024.	0.8	1
257	Medical oncologistsâ€™ experience with returning molecular tumor profiling to patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10521-10521.	0.8	1
258	Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	1
259	Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results.. <i>Health Psychology</i> , 2022, 41, 396-408.	1.3	1
260	Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 8201-8210.	1.0	1
261	Reply to A. Giacalone et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4175-4176.	0.8	0
262	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv206.	3.0	0
263	Radiation Therapy Deviations in Trial of Locally Advanced Pancreatic Cancerâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1409.	3.8	0
264	Destructive soft tissue metastases in advanced colorectal cancer: a case report. <i>Annals of Palliative Medicine</i> , 2021, .	0.5	0
265	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. <i>Psycho-Oncology</i> , 2021, 30, 1920-1929.	1.0	0
266	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 348-348.	0.8	0
267	ABC; An AGITC trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC). <i>Journal of Clinical Oncology</i> , 2007, 25, 15015-15015.	0.8	0
268	ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3643-TPS3643.	0.8	0
269	Usefulness of medical oncologistsâ€™ estimates of survival time in people with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9087-9087.	0.8	0
270	PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4137-TPS4137.	0.8	0



#	ARTICLE	IF	CITATIONS
271	Should culture affect practice? Prognostic discussions with immigrants.. Journal of Clinical Oncology, 2013, 31, 6556-6556.	0.8	0
272	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. Journal of Clinical Oncology, 2014, 32, 438-438.	0.8	0
273	Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. Journal of Clinical Oncology, 2015, 33, e15299-e15299.	0.8	0
274	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. Journal of Clinical Oncology, 2016, 34, 382-382.	0.8	0
275	Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.. Journal of Clinical Oncology, 2020, 38, 1541-1541.	0.8	0
276	Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.. Journal of Clinical Oncology, 2020, 38, e24080-e24080.	0.8	0
277	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51.	1.1	0
278	Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.. Journal of Clinical Oncology, 2022, 40, 3073-3073.	0.8	0
279	Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.. Journal of Clinical Oncology, 2022, 40, e18581-e18581.	0.8	0
280	The psychosocial impact of the Australian Rare Cancer Portal on patients with rare cancer.. Journal of Clinical Oncology, 2022, 40, e24127-e24127.	0.8	0